Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,988 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer Disease Dementia Clear all
Terminated Phase 2 Interventional

Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease

NCT00704782
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
dimebon
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Phoenix, Arizona • Sun City, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 15, 2026, 2:45 AM EDT
Terminated Early Phase 1 Interventional

Brain Imaging in the Diabetes Prevention Program Outcomes Study

NCT03757910
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-MK-6240, 11C-PIB
Drug
Lead sponsor
José A. Luchsinger
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 15, 2026, 2:45 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Biological Sample Collection for Research and Biobanking

NCT04270604
View directory record Official record
Conditions
Parkinson Disease, Diabetes Mellitus, Type 1, Macular Degeneration, ALS, Cancer, Alzheimer Disease, Huntington Disease
Interventions
Biological sample collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
1 Month to 100 Years
Enrollment
1,279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects

NCT00825084
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 15, 2026, 2:45 AM EDT
Not listed Phase 2 Interventional

Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease

NCT00174525
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AAB-001
Drug
Lead sponsor
Pharmacology Research Institute
Other
Eligibility
50 Years to 85 Years
Timeline
2005 – 2008
U.S. locations
2
States / cities
Los Alamitos, California • Northridge, California
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

NCT00824590
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2009 · Synced Oct 15, 2026, 2:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease

NCT02021682
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Not applicable Interventional

Vestibular Physical Therapy for People With Alzheimer Disease

NCT03887923
View directory record Official record
Conditions
Vestibular Diseases, Alzheimer Disease, Cognitive Impairment
Interventions
Vestibular Physical Therapy
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

NCT02509117
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06751979 single ascending dose, Placebo single dose, PF-06751979 multiple ascending dose, Placebo multiple dose, PF-06751979 multiple dose
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 15, 2026, 2:45 AM EDT
Terminated Phase 1 Interventional

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

NCT02220738
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-957, Placebo for ABT-957
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 90 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Glendale, California • Orlando, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

NCT00722046
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04360365 0.1 mg/kg, PF-04360365 0.5 mg/kg, PF-04360365 1 mg/kg, Placebo, PF-04360365 3 mg/kg, PF-04360365 8.5 mg/kg
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
15
States / cities
Peoria, Arizona • Phoenix, Arizona • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 15, 2026, 2:45 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

n-3 PUFA for Vascular Cognitive Aging

NCT01953705
View directory record Official record
Conditions
Age Related Cognitive Decline, Alzheimer's Disease, Vascular Dementia, Endothelial Dysfunction, Executive Dysfunction
Interventions
Omega 3 PUFA, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
75 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Phase 2 Interventional

Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease

NCT03867253
View directory record Official record
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
ORY-2001 Low dose, ORY-2001 High dose, Placebo
Drug
Lead sponsor
Oryzon Genomics S.A.
Industry
Eligibility
50 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Wellington, Florida • Columbus, Georgia • Princeton, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 15, 2026, 2:45 AM EDT
Not listed Phase 1 Interventional

A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's

NCT06309147
View directory record Official record
Conditions
Parkinson Disease
Interventions
BMS-9894923
Drug
Lead sponsor
Allyx Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Webnovela for Hispanic Dementia Family Caregivers

NCT02489110
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Webnovela, Information
Behavioral
Lead sponsor
Photozig, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Moffett Field, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 15, 2026, 2:45 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PET Changes in Alzheimer's Disease (AD)

NCT00094913
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
20 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2009 · Synced Oct 15, 2026, 2:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Finger Prick Collection Method for Measuring Alzheimer's Disease Blood Biomarkers

NCT07187921
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
Banner Health
Other
Eligibility
50 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Not applicable Interventional Results available

Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients

NCT01504958
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS), NICE Cognitive Training
Device · Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
55 Years to 90 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 15, 2026, 2:45 AM EDT
Recruiting Not applicable Interventional

The BRAIN App (Phase 2 SBIR)

NCT06298474
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Vascular Dementia
Interventions
The BRAIN App
Behavioral
Lead sponsor
Hopeful Aging
Industry
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winchester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 15, 2026, 2:45 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genetic Studies of Early-onset Dementia

NCT04906863
View directory record Official record
Conditions
Dementia, Early Onset, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Memory Loss
Interventions
Blood draw, Neurocognitive testing, Medical questionnaire
Genetic · Other
Lead sponsor
Columbia University
Other
Eligibility
35 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 15, 2026, 2:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

REVEAL III: Risk Evaluation and Education for Alzheimer's Disease

NCT00462917
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Pleiotropic info, in-person disclosure, AD-only info, in-person disclosure, Pleiotropic info, phone disclosure, AD-only info, phone disclosure
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 15, 2026, 2:45 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia

NCT00966017
View directory record Official record
Conditions
Down Syndrome, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
45 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2009 · Synced Oct 15, 2026, 2:45 AM EDT
Withdrawn Not applicable Interventional

Health-eBrain Study

NCT02903862
View directory record Official record
Conditions
Depression and Burden in Caregivers
Interventions
Mindoula, DANA
Behavioral · Device
Lead sponsor
AnthroTronix, Inc.
Industry
Eligibility
45 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 15, 2026, 2:45 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

NCT06125951
View directory record Official record
Conditions
Dementia Moderate, Dementia, Mild, Alzheimer Disease
Interventions
Xanamem, Placebo
Drug
Lead sponsor
Actinogen Medical
Industry
Eligibility
50 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 2:45 AM EDT